Literature DB >> 18337683

Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions.

S Basu1, J Kung, M Houseni, H Zhuang, G F Tidmarsh, A Alavi.   

Abstract

AIM: In this study, the fluorodeoxyglucose (FDG) uptake was prospectively investigated in tumors as well as the normal organs over 8 h in patients with non small cell lung carcinoma (NSCLC). The intent of this study was to collect positron emission tomography (PET) data with regard to the time course of FDG uptake in the primary and metastatic sites and the normal tissues over extended time periods (up to 8 h) after intravenous FDG injection in patients.
METHODS: Three patients (2 males, 1 female; mean age: 64 years; age range: 57-76 years) with the diagnosis of NSCLC underwent a series of whole body FDG-PET at several time points, beginning at 5 min and extending up to 8 h after the intravenous administration of FDG. We calculated the standardized uptake values (SUVmax) in the malignant lesions and all organs. SUVmax was calculated over contiguous slices and the highest value was considered for the analysis. Similar locations were used for the placement of regions of interest in subsequent images. Time activity curves (TACs) were generated utilizing these SUV values for each of these sites. The ratios of the SUVmax of the malignant lesions to those of normal organs (viz. lung and liver) at specific time points were also calculated and the TACs for these ratios were generated. The blood and plasma decay curves of (18)F activity over time were generated based on the counts obtained from blood sample analysis. The ratios of 18F activity of blood to plasma were also calculated and the TACs of this ratio were generated.
RESULTS: The observed mean SUVmax at different time points (5 min, 1 h, 2 h, 4 h, 6 h and 8 h) in the organs and the lesions were as follows: 1) heart: 2.9, 2, 1.9, 1.6, 1.3, 1.5; 2) kidney: 3.3, 3.5, 2.6, 2.1, 2, 2; 3) liver: 3.9, 2.2, 1.9, 1.6, 1.5, 1.8; 4) lung: 0.6, 0.5, 0.4, 0.4, 0.4, 0.4, 0.4; 5) large bowel: 2.1, 1.4, 1.8, 1.4, 2, 2.2; 6) small bowel: 2.6, 1.6, 1.4, 1.2, 1.3, 1.5; 7) lung neoplasm: 3.7, 5.1, 6.1, 6.8, 6.9, 6.8; 8) mediastinal lesion 1: 6.8, 8.8, 13, 12.7, 13.8, 12.5; 9) mediastinal lesion 2: 5.5, 8.6, 10.7, 13.2, 11.7, 12.1; 10) adrenal metastasis (starting at 1 h): 3.3, 3.7, 4.7, 4.7, 4.7; 11) right iliac metastasis: 2.6, 2.6, 3.1, 3.5, 3.4. For the right iliac metastasis, we had SUVmax up to 6 h. The SUVmax ratios of malignant lesions to those of normal lung and liver and their TACs demonstrate initial rise followed by a delayed plateau. Increasing (18)F count ratios of blood to plasma with time was observed in 2 patients where these data were available.
CONCLUSIONS: The results from this preliminary study indicate that while the tumor sites show increased uptake of FDG during the course of 8 h, surrounding normal tissues demonstrate declining or stable values with time. This would indicate increasing contrast between the lesion and the background and, therefore, possibly improved sensitivity of the test. While the high SUV at 5 min can be explained by the blood pool activity in the organs and the malignant lesions, the SUVmax values at the later times decreases or remains the same in normal organs. The observation on the different slopes of the curves among the various malignant lesions can be partly explained by the well known ''seed and soil'' theory in cancer biology. The finding of continued increases in the blood to plasma count ratios of (18)F activity is also noteworthy and most likely reflects GLUT-1 mediated glucose transport into red blood cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18337683

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  19 in total

1.  Suboptimal and inadequate quantification: an alarming crisis in medical applications of PET.

Authors:  Sandip Basu; Thomas C Kwee; Drew Torigian; Babak Saboury; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-18       Impact factor: 9.236

Review 2.  Defining the role of modern imaging techniques in assessing lymph nodes for metastasis in cancer: evolving contribution of PET in this setting.

Authors:  Thomas C Kwee; Sandip Basu; Drew A Torigian; Babak Saboury; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-12       Impact factor: 9.236

3.  Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results.

Authors:  Sofie Bæk Christlieb; Casper Nørgaard Strandholdt; Birgitte Brinkmann Olsen; Karen Juul Mylam; Thomas Stauffer Larsen; Anne Lerberg Nielsen; Max Rohde; Oke Gerke; Karen Ege Olsen; Michael Boe Møller; Bjarne Winther Kristensen; Niels Abildgaard; Abass Alavi; Poul Flemming Høilund-Carlsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-22       Impact factor: 9.236

4.  FDG-PET/CT can rule out malignancy in patients with vocal cord palsy.

Authors:  Anders Thomassen; Anne Lerberg Nielsen; Jeppe Kiilerich Lauridsen; Björn Alexander Blomberg; Søren Hess; Henrik Petersen; Allan Johansen; Jon Thor Asmussen; Jesper Roed Sørensen; Jørgen Johansen; Christian Godballe; Poul Flemming Høilund-Carlsen
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

5.  FDG-PET imaging to detect and characterize infectious disorders; an unavoidable path for the foreseeable future.

Authors:  Abass Alavi; Thomas J Werner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03       Impact factor: 9.236

6.  Ultra staging to unmask the prescribing of adjuvant therapy in cancer patients: the future opportunity to image micrometastases using total-body 18F-FDG PET scanning.

Authors:  Patricia M Price; Ramsey D Badawi; Simon R Cherry; Terry Jones
Journal:  J Nucl Med       Date:  2014-03-06       Impact factor: 10.057

7.  Impacts of biological and procedural factors on semiquantification uptake value of liver in fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging.

Authors:  Mohd Hafizi Mahmud; Abdul Jalil Nordin; Fathinul Fikri Ahmad Saad; Ahmad Zaid Fattah Azman
Journal:  Quant Imaging Med Surg       Date:  2015-10

Review 8.  18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization.

Authors:  Hossein Jadvar; Abass Alavi; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

9.  Time sensitivity: a parameter reflecting tumor metabolic kinetics by variable dual-time F-18 FDG PET imaging.

Authors:  Ching-yee Oliver Wong; Daniel Noujaim; Hungsen F Fu; Wen-sheng Huang; Cheng-yi S Cheng; Joseph Thie; Ishani Dalal; Chih-yung Chang; Conrad Nagle
Journal:  Mol Imaging Biol       Date:  2009-03-27       Impact factor: 3.488

Review 10.  FDG PET/CT in carcinoma of unknown primary.

Authors:  Thomas C Kwee; Sandip Basu; Gang Cheng; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-31       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.